Research programme: Syk kinase inhibitors - GlaxoSmithKline
Latest Information Update: 16 Jul 2016
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Indazoles; Pyrimidines; Small molecules
- Mechanism of Action Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Hypersensitivity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allergy in United Kingdom (Intranasal)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allergy in United Kingdom (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in United Kingdom (Intranasal)